For example, ANP32B is highly expressed in patients diagnosed with chronic myelogenous leukemia (CML), whereas deletion of ANP32B enhances p53 transcriptional activity and synergizes therapeutically with tyrosine kinase inhibitors to inhibit CML propagation [16]. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.